Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLB-001
- Development stage
- Unknown
- Lead developer
- Primelink BioTherapeutics
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
PLB-001: sourced facts only. name: "Here, we present a novel DLL3 targeted ADC, PLB-001, which using a highly potent topoisomerase I inhibitor exatecan, conjugated to a humanized IgG1 antibody, through a highly hydrophilic, enzyme-cleavable linker with a DAR of 8." [DOI:10.1158/1538-7445.am2025-4746]; target: "Here, we present a novel DLL3 targeted ADC, PLB-001, which using a highly potent topoisomerase I inhibitor exatecan, conjugated to a humanized IgG1 antibody, through a highly hydrophilic, enzyme-cleavable linker with a DAR of 8." [DOI:10.1158/1538-7445.am2025-4746]; developer: "PrimeLink BioTherapeutics, suzhou, China." [DOI:10.1158/1538-7445.am2025-4746]; modality: "Here, we present a novel DLL3 targeted ADC, PLB-001, which using a highly potent topoisomerase I inhibitor exatecan, conjugated to a humanized IgG1 antibody, through a highly hydrophilic, enzyme-cleavable linker with a DAR of 8." [DOI:10.1158/1538-7445.am2025-4746]
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on PLB-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLB-001.